RORA and cancer: According to our data, the dose of atorvastatin in combination with RORα/γ agonists required to achieve certain cytotoxicity in cancer cells is several to dozens of folds lower than that required for atorvastatin alone (Fig. 6C, Supplementary Tables 2–4), a very exciting advantage for future application of these drugs in combination.